hit counter
Acer Therapeutics Inc. (ACER) Stock News Sentiment & Price - Sentifly
ACER - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Acer Therapeutics Inc. (ACER)

USA
Biotechnology
NASDAQ
ACER Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACER Latest news
GlobeNewsWire
Neutral
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation
2021-10-26 08:30

Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036 Key ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036

Zacks Investment Research
Positive
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance
2021-10-07 12:10

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022.

GlobeNewsWire
Neutral
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
2021-10-07 08:30

Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036

GlobeNewsWire
Neutral
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders
2021-10-06 08:30

FDA sets PDUFA target action date of June 5, 2022 FDA sets PDUFA target action date of June 5, 2022

Benzinga
Positive
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
2021-10-06 07:21

The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's  (OTC: RLFTF) marketing application for ACER-001 (sodium phenylbutyrate) for Urea Cycle Disorders (UCDs).  Related:   Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics.

Pulse2
Positive
ACER Stock: Why It Increased Today
2021-10-06 07:03

The stock price of Acer Therapeutics Inc (NASDAQ: ACER) increased by over 15% pre-market today. This is why it happened.

Seeking Alpha
Positive
Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases
2021-08-31 18:43

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August.

GlobeNewsWire
Neutral
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-30 08:30

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

Zacks Investment Research
Negative
Opexa Therapeutics, Inc. (ACER) Reports Q2 Loss, Misses Revenue Estimates
2021-08-10 20:04

Opexa Therapeutics, Inc. (ACER) delivered earnings and revenue surprises of 36.11% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update
2021-08-10 16:05

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2021 and provided an update on the Company's recent corporate developments.

Loading more news...